Genomic classifier (GC) tests do not appear to consistently influence risk classification or treatment decisions for patients with newly diagnosed prostate cancer considering first-line treatment, ...
Tests do not consistently influence risk classification or treatment decisions; authors call for well-designed trials on role of GC tests in newly diagnosed PCa. (HealthDay News) — For patients with ...
Enrollment Success, Factors, and Prediction Models in Cancer Trials (2008-2019) Men with potentially lethal PC (metastatic, localized with a Gleason score of ≥8, persistent prostate-specific antigen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results